| Title |
Molecular mechanisms of cisplatin resistance in cervical cancer
|
|---|---|
| Published in |
Drug Design, Development and Therapy, June 2016
|
| DOI | 10.2147/dddt.s106412 |
| Pubmed ID | |
| Authors |
Haiyan Zhu, Hui Luo, Wenwen Zhang, Zhaojun Shen, Xiaoli Hu, Xueqiong Zhu |
| Abstract |
Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year survival is only 10%-20%. Chemotherapy is considered as the standard treatment for patients with advanced or recurrent cervical cancer, and cisplatin appears to treat the disease effectively. However, resistance to cisplatin may develop, thus substantially compromising the efficacy of cisplatin to treat advanced or recurrent cervical cancer. In this article, we systematically review the recent literature and summarize the recent advances in our understanding of the molecular mechanisms underlying cisplatin resistance in cervical cancer. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 280 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 280 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 44 | 16% |
| Student > Ph. D. Student | 37 | 13% |
| Student > Bachelor | 36 | 13% |
| Researcher | 18 | 6% |
| Student > Doctoral Student | 16 | 6% |
| Other | 35 | 13% |
| Unknown | 94 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 73 | 26% |
| Medicine and Dentistry | 34 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 5% |
| Chemistry | 14 | 5% |
| Agricultural and Biological Sciences | 11 | 4% |
| Other | 31 | 11% |
| Unknown | 102 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 July 2020.
All research outputs
#16,063,069
of 25,394,764 outputs
Outputs from Drug Design, Development and Therapy
#929
of 2,270 outputs
Outputs of similar age
#203,981
of 353,760 outputs
Outputs of similar age from Drug Design, Development and Therapy
#29
of 65 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,270 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,760 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.